An HPLC–MS/MS method for simultaneous determination of decitabine and its valyl prodrug valdecitabine in rat plasma

This publication has 10 references indexed in Scilit:

• Development and validation of a liquid chromatography–tandem mass spectrometry method for quantification of decitabine in rat plasma
  Journal of Chromatography B, 2012
• A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
  Haematologica, 2011
• Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies
  Journal of Chromatography B, 2007
• Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
  Cancer Chemotherapy and Pharmacology, 2007
• Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
  Blood, 2006
• Decitabine improves patient outcomes in myelodysplastic syndromes
  Cancer, 2006
• Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5‐aza‐2′‐deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method
  Rapid Communications in Mass Spectrometry, 2006
• Chronic myelogenous leukemia in nonlymphoid blastic phase
  Cancer, 1999
• Sample preparation for the determination of 5-aza-2′-deoxycytidine in plasma by high-performance liquid chromatography
  Journal of Chromatography B: Biomedical Sciences and Applications, 1985
• Sample Preparation and Estimation of Plasma Concentration of 3-Deazauridine by High-Performance Liquid Chromatography
  Therapeutic Drug Monitoring, 1983